A brain-penetrant enzyme-replacement drip for MPS II (Hunter syndrome)
Pabinafusp alfa
An enzyme-replacement drip used to treat MPS II (Hunter syndrome), a rare inherited condition, and designed to reach the brain.
What is Pabinafusp alfa?
Pabinafusp alfa is a specialist enzyme-replacement medicine used to treat mucopolysaccharidosis type II (MPS II, also called Hunter syndrome), a rare inherited condition in which a missing enzyme lets complex sugars build up and damage many organs, including the brain. It is a fusion enzyme designed to cross into the brain, where many older enzyme treatments cannot reach. It works by replacing the missing enzyme so the body can break down the build-up. It is given as a drip into a vein under specialist care, with infusion-associated reactions, including serious allergic reactions, being the main concern.
Education and reference only. This is a plain-language guide to Pabinafusp alfa — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Pabinafusp alfa is an enzyme-replacement therapy for MPS II (Hunter syndrome), a rare inherited condition in which a lack of an enzyme (iduronate-2-sulfatase) lets complex sugars called glycosaminoglycans build up in cells throughout the body, damaging organs and, in many people, the brain. Pabinafusp alfa is specially designed as a fusion enzyme that can cross into the brain, which standard enzyme treatments struggle to reach. It is a manufactured copy of the missing enzyme joined to a part that helps brain entry, given as a drip into a vein. It is started and supervised by a specialist team.
How it works
In MPS II, the missing enzyme means complex sugars cannot be broken down, so they accumulate in cells and damage tissues over time, including the brain in many people. Pabinafusp alfa supplies the missing enzyme to help clear that build-up. What makes it different is that it is attached to a part that helps it cross from the blood into the brain, so it can act on the build-up affecting the nervous system as well as the body. Because the enzyme only works while it is present, it is given as regular infusions to keep its effect going.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist enzyme-replacement medicine used to treat MPS II (Hunter syndrome), including its effects on the brain.
Practical use
How to take Pabinafusp alfa
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Have it as a drip into a vein, on a regular schedule, in a setting where reactions can be managed.
- Expect the drip to be given slowly, and tell staff straight away if you feel unwell during it.
- Watch for reactions during or soon after the drip, such as fever, rash, flushing or feeling faint.
- Seek urgent help for any signs of a serious allergic reaction, such as difficulty breathing or swelling of the face.
- Do not skip or stop treatment without specialist advice, as the benefits depend on keeping it going.
Weighing it up
Advantages & disadvantages of Pabinafusp alfa
Advantages
- Replaces the missing enzyme in MPS II, helping clear the build-up that damages organs.
- Designed to cross into the brain, addressing nervous-system effects that some enzyme treatments cannot reach.
- Offers a targeted treatment for a progressive condition with otherwise limited options.
Disadvantages
- Given as a drip into a vein on a regular, long-term schedule.
- Can cause infusion-associated reactions, including serious allergic reactions.
- Requires ongoing specialist monitoring and supervision.
Practical use
Good to know
The distinctive point about pabinafusp alfa is that it is a brain-penetrant fusion enzyme, designed to reach the nervous system as well as the rest of the body, which matters because the brain effects of MPS II are not addressed by enzyme treatments that cannot cross into the brain. It is given as a drip into a vein, regularly and for the long term, in a setting where reactions can be managed. Infusion-associated reactions are the main concern, ranging from mild effects such as fever, rash or flushing during the drip to serious allergic and anaphylactoid reactions, so the drip may be slowed or stopped and medicines given if needed. It should not be stopped without specialist advice, and the team monitors response, including nervous-system signs, over time.
Who should not take it / use with caution
- People who have had a serious allergic reaction to pabinafusp alfa should not use it.
- It is used with care, and with close monitoring, in people who have had reactions to enzyme-replacement treatment before.
- It should only be used under specialist supervision where infusion reactions can be managed.
Monitoring
- Watching closely for infusion-associated and allergic-type reactions during and after each drip.
- Reviewing how the condition responds, including nervous-system and developmental signs.
- Checking overall response and adjusting care as needed.
Side effects
- Reactions during or soon after the drip, such as fever, rash, flushing, headache or feeling unwell.
- Nausea, vomiting or tummy upset in some people.
- Rarely, serious allergic or anaphylactoid reactions, which need urgent treatment.
Key interactions
- There are few well-established routine medicine interactions, but tell your team about everything you take.
- Medicines used to manage infusion reactions, such as antihistamines, may be given around the drip.
- Tell your team about any previous reactions to enzyme-replacement treatment.
Available as: A solution given as a drip (infusion) into a vein.
Answers
Pabinafusp alfa: frequently asked questions
What is pabinafusp alfa used for?
It is used to treat MPS II (Hunter syndrome), a rare inherited condition in which a missing enzyme lets complex sugars build up and damage organs, including the brain, by replacing that enzyme.
Why is it described as brain-penetrant?
It is a fusion enzyme designed to cross from the blood into the brain, so it can act on the nervous-system effects of MPS II that some enzyme treatments cannot reach.
How is it given?
It is given as a drip (infusion) into a vein on a regular schedule, in a setting where any reactions can be managed by the specialist team.
What are the main risks?
The main risk is a reaction during or soon after the drip, ranging from mild effects to serious allergic reactions, which is why it is given where these can be managed.
Can it be stopped once the build-up improves?
No. It is a long-term treatment whose benefits depend on continuing it, so only change or stop it on specialist advice.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.